Health and Fitness Health and Fitness
Thu, August 30, 2012
Wed, August 29, 2012
Tue, August 28, 2012
Mon, August 27, 2012
Sun, August 26, 2012
Sat, August 25, 2012
Fri, August 24, 2012
Thu, August 23, 2012
Wed, August 22, 2012
[ Wed, Aug 22nd 2012 ] - Market Wire
Inergetics Shareholder Update
Tue, August 21, 2012
Mon, August 20, 2012
[ Mon, Aug 20th 2012 ] - Market Wire
Watson Launches Generic Xopenex
Sat, August 18, 2012
Fri, August 17, 2012
Thu, August 16, 2012
Wed, August 15, 2012
Tue, August 14, 2012
Mon, August 13, 2012
Fri, August 10, 2012

Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference


//health-fitness.news-articles.net/content/2012/ .. -2012-stifel-nicolaus-healthcare-conference.html
Published in Health and Fitness on Thursday, August 23rd 2012 at 12:31 GMT by Market Wire   Print publication without navigation


Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference -- ATLANTA, Aug. 23, 2012 /PRNewswire/ --

Alimera Sciences To Present At 2012 Stifel Nicolaus Healthcare Conference

[ ]

ATLANTA, Aug. 23, 2012 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: [ ALIM ]) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Rick Eiswirth, Chief Operating Officer and Chief Financial Officer, will present at the Stifel Nicolaus Healthcare Conference at 3:15 P.M. ET on Thursday, September 6, 2012 in Boston, MA.

The presentation will be webcast live and can be accessed on the Investor Relations section of the corporate website at [ http://www.alimerasciences.com ]. For those who are not available to listen to the live broadcast, the webcast will be archived for 30 days.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.

ICR, LLC

for Alimera Sciences

John Mills

310-954-1105

[ John.Mills@icrinc.com ]


SOURCE Alimera Sciences, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.alimerasciences.com ]


Publication Contributing Sources